Allarity Therapeutics $3M Debt Financing with Streeterville Capital, LLC
Allarity Therapeutics entered into an exchange agreement with Streeterville Capital to partition $3.0 million from an existing $10.93 million promissory note. The partitioned debt was exchanged for 3,000 shares of newly designated Series B Preferred Stock, effectively reducing the company's outstanding debt balance by $3.0 million. The Series B Preferred Stock carries a 9% annual dividend and ranks senior to common stock in liquidation.
For the nine months ended September 30, 2026, Allarity Therapeutics reported a net loss of $12.4 million, an increase from the $7.9 million loss in the prior year period, primarily driven by higher research and development costs. The company's total stockholders' equity turned to a deficit of $2.3 million as of September 30, 2026, while cash and restricted cash increased to approximately $24.1 million.
Allarity Therapeutics Wins Contract from unnamed European biotechnology company
Allarity Therapeutics secured its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy. The company will provide development and validation services to support a European biotechnology company's precision oncology predictive device in the U.S. market.
Allarity Therapeutics Deal Termination with Tumim Stone Capital LLC
Allarity Therapeutics terminated its Common Stock Purchase Agreement with Tumim Stone Capital, effective October 28, 2026. The agreement had allowed the company to sell up to $6.0 million of common stock at its discretion, but Allarity elected to cancel the facility to pursue alternative financing arrangements. No early termination penalties were incurred as a result of the cancellation.
Allarity Therapeutics provided an operational update regarding its proprietary Drug Response Predictor (DRP) technology, patent portfolio, and in-house laboratory capabilities. The company highlighted that higher DRP scores were associated with longer overall survival in ovarian cancer patients treated with stenoparib, supporting its strategy to use the technology for patient selection in upcoming pivotal trials.
Allarity Therapeutics has expanded its in-house medical laboratory capabilities to include proteomics and cell line research. These new capabilities will support deeper mechanism-of-action research for its lead asset, stenoparib, and allow the company to offer a broader range of research services to external partners. The expansion is expected to create cost efficiencies without impacting the company's current cash runway.
Allarity Therapeutics has been granted Japanese Patent No. 7917283 by the Japan Patent Office, covering its proprietary stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. The patent provides intellectual property protection in Japan through 2039 for methods of predicting clinical benefit and selecting patients for stenoparib treatment. This follows similar patent protections already secured in the United States, Europe, and Australia.
Allarity Therapeutics announced that its newly formed SPAC, Allarity Acquisition Corp., has filed a Registration Statement for a proposed $100 million IPO ($115 million including overallotment). Allarity's subsidiary will act as the sponsor and is expected to own approximately 25% of the SPAC following the offering.